

A prospective study using the KerraCel™ dressing on multiple wound types

Submission date 15/09/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 15/11/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 20/11/2025	Condition category Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

The KerraCel™ dressing is a CE-marked product that has been on the market since 2013. It contains gelling fibers that can soak up the fluid that can be created by wounds on the skin. The aim of the study is to collect additional information on the dressing to show that it is working as intended.

Who can participate?

Patients aged 22 years or older and being seen for these types of wounds: Oncology wounds, traumatic wounds, cavity wounds, skin donor site. Examples of these can be: Oncology - radiation burns, cancerous wounds or wounds that occur after surgical removal of cancer. Traumatic - abrasions (deep scrapes) or lacerations. Cavity - wounds in a cavity (such as abdomen or chest). Donor sites where skin has been removed for grafting.

What does the study involve?

For patients who meet the requirements to participate, you will be seen 4 times in the office /clinic. On the first visit, you will have a picture taken of the wound and the dressing put over the wound. You will come in 2 additional times, approximately 7 days apart from each visit, to have another picture of the wound taken and another dressing placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture is taken. No surveys will be completed for this study and only small amounts of information such as medical history, medication use, and information about your wound will be collected.

What are the possible benefits and risks of participating?

Possible benefits of the study are the wound dressing may help manage your wound healing, additional follow-up by the staff at the hospital since this is a study, use of a dressing not currently in use at the facility.

Possible risks of participating are the same risks that would occur for treating any open wound with a wound dressing: skin irritation, redness, possible infection, delay in wound healing. One possible risk for this type of dressing is some of the gel material could remain in the wound.

Where is the study run from?
Wythenshawe Hospital (UK)

When is the study starting and how long is it expected to run for?
April 2021 to June 2023

Who is funding the study?
KCI® USA, Inc (now a part of 3M) (USA)

Who is the main contact?
Mrs Lawrie Rogerson-Wynne, Lawrie.rogerson@mft.nhs.uk

Contact information

Type(s)

Public

Contact name

Mrs Lawrie Rogerson-Wynne

Contact details

Research Office, First floor, NIHR Research Building
Wythenshawe Hospital
Southmoor Road
Manchester
United Kingdom
M23 9QZ
+44 (0)161 291 4850
Lawrie.rogerson@mft.nhs.uk

Type(s)

Scientific

Contact name

Mr Eric Synatschk

Contact details

KCI USA, Inc.
6203 Farinon Drive
San Antonio
United States of America
78249
+1 5126625943
esynatschk@mmm.com

Additional identifiers

Integrated Research Application System (IRAS)
288315

Central Portfolio Management System (CPMS)

47700

Protocol serial number

KERA_CEL-PMCF007

Study information

Scientific Title

A prospective, observational, Post Market Clinical Follow-up (PMCF) study in patients using 3M™ KerraCel™ Gelling Fiber dressing

Study objectives

Current hypothesis as of 18/03/2022:

The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on the identified wound types, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

Previous hypothesis:

The aim of this study is to describe the population and indications of the KerraCel™ Dressing to demonstrate that the product is performing as expected and is safe specifically on oncological and traumatic wounds, where it has been identified that additional evidence is needed to support the Clinical Evaluation Report (CER).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 23/04/2021, London-Westminster Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8388; westminster.rec@hra.nhs.uk), ref: 21/PR/0337

Study design

Single center observational study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Oncological wounds (e.g. radiation burns, cancerous wounds and surgical wounds once the cancerous tissue has been removed), traumatic wounds (e.g. abrasions and lacerations), cavity wounds (such as abdominal or thoracic) and wounds created from skin donor sites

Interventions

Patients will be seen and evaluated by a clinician to determine if their wound is appropriate to be treated with the KerraCel™ dressing. If yes, the clinician will make general observations of the wound and then dress the wound. Pictures will be taken of the wound initially and at each dressing change.

Patients will be seen 4 times in the office/clinic. On the first visit, a picture is taken of the wound and the dressing put over the wound. At 2 additional visits, approximately 7 days apart from each visit, another picture of the wound is taken and another dressing is placed over the wound. A final visit will occur (again approximately 7 days from the 3rd visit), where the dressing will be removed and another picture taken.

Intervention Type

Device

Phase

Phase IV

Drug/device/biological/vaccine name(s)

3M™ KerraCel™ Gelling Fiber Dressing

Primary outcome(s)

Treatment-related adverse events measured using patient records up to the final visit (~21-28 days)

Key secondary outcome(s)

Wound healing and wound bed preparation by visual inspection of at baseline, ~day 7, 14, 21-28:

1. Decrease in wound size (volume, area, or depth)
2. Increase in % of wound granulation tissue
3. Wound moisture evaluation defined as wound exudate levels indicated as optimal
4. Decrease in % of nonviable tissue

Completion date

21/06/2023

Eligibility

Key inclusion criteria

Current inclusion criteria as of 18/03/2022:

1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous tissue has been removed), or traumatic wound (e.g. abrasions and lacerations), or cavity wound (wounds in a cavity) or skin donor site
2. Must be able to provide informed consent
3. Only one wound may be treated per subject for the study
4. Aged ≥ 22 years

Previous inclusion criteria:

1. Subjects who have been diagnosed with an oncological wound (e.g. radiation burns, cancerous wounds, and surgical wounds once the cancerous issue has been removed) or traumatic (e.g. abrasions and lacerations) wound.
2. Must be able to provide informed consent.

3. Only one wound may be treated per subject for the study.
4. Age ≥ 22 years.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

22 years

Upper age limit

100 years

Sex

All

Total final enrolment

48

Key exclusion criteria

Current exclusion criteria as of 18/03/2022:

1. Has a known allergy to the dressing material
2. Has a wound that has uncontrolled heavy bleeding
3. Wound or burn larger than 20 cm in any direction
4. Pregnant or breastfeeding

Previous exclusion criteria:

1. Has a wound that requires packing of a body cavity with the KerraCel™ dressing, per the manufacturer's instructions for use.
2. Has a wound that has not achieved hemostasis, per the manufacturer's instructions for use.
3. Wound or burn larger than 20cm in any direction.
4. Pregnant or breastfeeding.

Date of first enrolment

01/09/2021

Date of final enrolment

09/06/2023

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Wythenshawe Hospital

University of Manchester & Manchester University NHS Foundation Trust

Southmoor Road

Manchester

England

M23 9QZ

Sponsor information

Organisation

KCI (United States)

ROR

<https://ror.org/00wc6ay63>

Funder(s)

Funder type

Industry

Funder Name

Kinetic Concepts

Alternative Name(s)

Kinetic Concepts, Inc., KCI USA, KCI

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

United States of America

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results			20/11/2025	No	No
HRA research summary			28/06/2023	No	No